Pas­sage Bio scraps a ther­a­py; XO­MA’s new loan; Im­pel is for sale

Plus, news on Im­priMed, blue­bird bio and Syn­dax.

Pas­sage Bio shakes up its pipeline: The Jim Wil­son-found­ed biotech is shelv­ing a ther­a­py for GM1 gan­gliosi­do­sis. It now plans to fo­cus on a pre­clin­i­cal Hunt­ing­ton’s gene ther­a­py and a gene ther­a­py for pa­tients with a form of de­men­tia af­ter re­port­ing safe­ty and bio­mark­er da­ta from three pa­tients, po­ten­tial­ly test­ing the treat­ment in oth­er adult neu­rode­gen­er­a­tive dis­eases. Pas­sage this year has gone through a se­ries of lead­er­ship changes and lay­offs and al­ready side­lined two pe­di­atric gene ther­a­py pro­grams for Krabbe dis­ease and metachro­mat­ic leukody­s­tro­phy. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER